Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.7K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

5.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
5.0K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pocket guide: biologics in upper and lower airways in adults.

Rhinology·2025
Same author

Do NO, N<sub>2</sub>O, N<sub>2</sub> and CO<sub>2</sub> fluxes differ in soils sourced from cropland and varying riparian buffer vegetation? An incubation study.

Soil use and management·2024
Same author

Pelvic Abscess.

Texas medical journal (Austin, Tex.)·2023
Same author

Naevi: Report of a Case and Treatment by Electrolysis.

Texas medical journal (Austin, Tex.)·2023
Same author

Soil CO<sub>2</sub> emissions in cropland with fodder maize (<i>Zea mays</i> L.) with and without riparian buffer strips of differing vegetation.

Agroforestry systems·2022
Same author

Soil N<sub>2</sub>O and CH<sub>4</sub> emissions from fodder maize production with and without riparian buffer strips of differing vegetation.

Plant and soil·2022
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K

Anti-interleukin therapy in asthma.

R M Dunn1, M E Wechsler

  • 1Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA.

Clinical Pharmacology and Therapeutics
|February 12, 2015
PubMed
Summary
This summary is machine-generated.

Targeted anti-interleukin therapies offer personalized asthma management by addressing specific inflammatory pathways. Understanding the risks and benefits of these treatments is crucial for clinicians and pharmacists.

More Related Videos

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

8.1K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

8.1K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.3K

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma is a prevalent and costly respiratory disease in the U.S., incurring significant medical expenditures and indirect costs.
  • Recent advancements recognize asthma's heterogeneity and the diverse inflammatory pathways involved.
  • Interleukins are key mediators in both eosinophilic and noneosinophilic asthma subtypes.

Purpose of the Study:

  • To highlight the role of interleukins in asthma pathogenesis.
  • To discuss the potential of anti-interleukin therapies for personalized asthma management.
  • To inform clinicians and pharmacists about the upcoming use of targeted anti-interleukin treatments.

Main Methods:

  • Review of recent large clinical trials on anti-interleukin therapies.
  • Analysis of the role of specific interleukins (IL-4, IL-5, IL-13) in asthma.
  • Synthesis of current understanding of asthma heterogeneity and inflammatory pathways.

Main Results:

  • Anti-interleukin (IL)-4, IL-5, and IL-13 therapies have shown success in specific asthmatic populations.
  • Targeted anti-interleukin therapies are anticipated for near-future approval.
  • These therapies represent a move towards personalized asthma treatment strategies.

Conclusions:

  • Anti-interleukin therapies are poised to become a significant advancement in asthma management.
  • Clinicians and pharmacists must be prepared to understand the risks, benefits, and appropriate indications for these novel treatments.
  • Personalized medicine approaches, guided by understanding inflammatory pathways, will improve asthma care.